For AML and CML, Qin et al. determined that in Caucasians and Asians, neither MTHFR polymorphism augment the risk of developing cancer (Qin et al., 2014). This evidence concerns the gene MTHFR and chronic myelogenous leukemia, BCR-ABL1 positive.